{"url_path":"/sec/juns/8-k/2026-07-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-034077-index.html","accession_number":"0001493152-26-034077","cik":"0001679628","ticker":"JUNS","issuer_name":"JUPITER NEUROSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-034077-index.html","primary_entity_key":"0001679628","primary_entity_name":"JUPITER NEUROSCIENCES, INC."},"word_count":144,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nIndex of Exhibits.\n\n \n\nExhibit\nNo.\n \nDescription\n\n \n \n \n\n10.1†\n \n[Strategic Asset License Agreement, dated as of July 20, 2026, by and between PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. (filed herewith).](ex10-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the\nInline XBRL document).\n\n \n\n†\nCertain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K\nbecause the omitted information is not material and is the type of information that the registrant customarily and actually treats as\nprivate or confidential.\n\n \n\n \n\n \n\n**  **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**JUPITER\nNEUROSCIENCES, INC.**\n\n \n \n \n\nDate:\nJuly 21, 2026\nBy:\n*/s/\nChrister Rosén*\n\n \nName:\nChrister\nRosén\n\n \nTitle: \nChairman,\nChief Executive Officer\n\n \n \n&\nFounder"}